These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21706866)

  • 21. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
    Mesa RA
    Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2016 WHO Classification update-What's new in lymphoid neoplasms.
    Hsi ED
    Int J Lab Hematol; 2017 May; 39 Suppl 1():14-22. PubMed ID: 28447410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
    Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
    Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
    Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Outline and direction of revised WHO classification of Tumors of Haematopoietic and Lymphoid Tissues].
    Tomonaga M
    Rinsho Ketsueki; 2009 Oct; 50(10):1401-6. PubMed ID: 19915348
    [No Abstract]   [Full Text] [Related]  

  • 29. [A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms].
    Kovrigina AM
    Arkh Patol; 2018; 80(6):43-49. PubMed ID: 30585592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
    Campbell P
    Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
    [No Abstract]   [Full Text] [Related]  

  • 31. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.
    Harris NL; Jaffe ES; Diebold J; Flandrin G; Muller-Hermelink HK; Vardiman J; Lister TA; Bloomfield CD
    Ann Oncol; 1999 Dec; 10(12):1419-32. PubMed ID: 10643532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synoptic tool for reporting of hematological and lymphoid neoplasms based on World Health Organization classification and College of American Pathologists checklist.
    Mohanty SK; Piccoli AL; Devine LJ; Patel AA; William GC; Winters SB; Becich MJ; Parwani AV
    BMC Cancer; 2007 Jul; 7():144. PubMed ID: 17672904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Jak2: normal function and role in hematopoietic disorders.
    Ihle JN; Gilliland DG
    Curr Opin Genet Dev; 2007 Feb; 17(1):8-14. PubMed ID: 17208428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Review of changes introduced by the new WHO classification (4th edition) of myeloid neoplasms. An overview].
    Komatsu N
    Rinsho Ketsueki; 2009 Mar; 50(3):127-33. PubMed ID: 19352078
    [No Abstract]   [Full Text] [Related]  

  • 35. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic/myeloproliferative disorders.
    Malcovati L; Cazzola M
    Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
    [No Abstract]   [Full Text] [Related]  

  • 38. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
    Ghaderi M; Strömberg O; Porwit A
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [From FAB classification to WHO classification of tumors of hematopoietic and lymphoid tissue].
    Yatomi Y
    Rinsho Byori; 2012 Jun; 60(6):550-2. PubMed ID: 23061109
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.